"The company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tizanidine Hydrochloride Capsules, 2 mg, 4 mg, and 6 mg," the drug firm said in a regulatory filing.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2NsYWEj
via IFTTT
0 comments:
Post a Comment